# A comparative study of the effectivity of MSC-based, NP-based and combined therapies in an experimental model of NaIO3-induced retinal degeneration

**Authors:** Katerina Palacka, Barbora Hermankova, Tereza Cervena, Pavel Rossner, Vladimir Holan, Eliska Javorkova

PMC · DOI: 10.1038/s41598-025-07727-7 · 2025-07-01

## TL;DR

This study compares the effectiveness of MSCs, nanoparticles, and their combination in treating retinal degeneration, finding that combined therapy reduces immunomodulatory effects.

## Contribution

The study reveals that combining MSCs with AgNPs decreases their immunomodulatory effects in retinal degeneration models.

## Key findings

- MSCs or AgNPs alone modulate inflammation in retinal degeneration.
- Combined MSCs and AgNPs reduce the immunomodulatory effects of each therapy.
- MSCs increase expression of retinal markers and growth factors like IGF-1 and GDNF.

## Abstract

Mesenchymal stem cells (MSCs) represent the promising options for retinal therapy and combined therapy with nanoparticles (NPs) could currently provide increased immunoregulatory and neuroprotective effects. Therefore, we tested the effect of silver (Ag)NPs on the properties of MSCs in an experimental model of chronic retinal degeneration. The results showed that simultaneous administration had no effect on the survival of MSCs, but a less effective local regulation of Iba-1 expression compared to MSC- or AgNP-only treated groups was observed. In addition, MSCs applied alone or in combination with AgNPs and sorted from the degenerated retina had increased expression of genes for retinal markers (rhodopsin, S-antigen, recoverin), and for TGF-β and IGF-1. These effects were confirmed also on protein level by increased production of IGF-1 and proportion of rhodopsin+ MSCs. Nevertheless, the increased expression of the gene for GDNF was observed only in the MSCs combined with AgNPs. Regarding the immune response, the application of MSCs with AgNPs triggered increased expression of the IL-6 gene in the CD45 cells separated from the retina. In conclusion, applications of MSCs or AgNPs, as a single therapy, were able to modulate the inflammation. However, the combined applications decreased the immunomodulatory effects of MSCs or AgNPs.

## Linked entities

- **Genes:** rhodopsin (rhodopsin-like) [NCBI Gene 102290933], SAG (S-antigen visual arrestin) [NCBI Gene 109374532], rcvrn.2.L (recoverin, gene 2 L homeolog) [NCBI Gene 447358], TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040], IGF1 (insulin like growth factor 1) [NCBI Gene 3479], GDNF (glial cell derived neurotrophic factor) [NCBI Gene 2668], IL6 (interleukin 6) [NCBI Gene 3569]
- **Proteins:** AIF1 (allograft inflammatory factor 1), IGF1 (insulin like growth factor 1), rhodopsin (rhodopsin-like)

## Full-text entities

- **Genes:** IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, RHO (rhodopsin) [NCBI Gene 6010] {aka CSNBAD1, OPN2, RP4}, AIF1 (allograft inflammatory factor 1) [NCBI Gene 199] {aka AIF-1, IBA1, IRT-1, IRT1}, GDNF (glial cell derived neurotrophic factor) [NCBI Gene 2668] {aka ATF, ATF1, ATF2, HFB1-GDNF, HSCR3}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, RCVRN (recoverin) [NCBI Gene 5957] {aka RCV1}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}
- **Diseases:** inflammation (MESH:D007249), chronic retinal degeneration (MESH:D012162)
- **Chemicals:** NaIO3 (MESH:C032285), Ag (MESH:D012834), AgNP (-)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12216528/full.md

---
Source: https://tomesphere.com/paper/PMC12216528